Nycomed Visipaque journal article referring to "new class" of contrast agent draws FDA objection.
Executive Summary
NYCOMED VISIPAQUE ARTICLE DESCRIPTION AS "NEW CLASS" DRAWS FDA OBJECTION in a Sept. 5 notice-of- violation letter. The Division of Drug Marketing, Advertising & Communications letter cites Nycomed for an article appearing in the August 1996 issue of Applied Radiology that refers to Visipaque (iodixanol) injection as a "new `isosmolar' class of radiographic contrast."